Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average rating of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $11.27.

HCAT has been the subject of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday. Evercore ISI increased their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Piper Sandler restated an “overweight” rating and set a $12.00 target price (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Finally, Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $5.49 on Tuesday. The stock has a 50 day moving average of $7.56 and a two-hundred day moving average of $7.51. Health Catalyst has a 12 month low of $5.35 and a 12 month high of $10.99. The firm has a market cap of $334.07 million, a P/E ratio of -4.07 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. The business’s revenue was up 3.5% on a year-over-year basis. On average, analysts expect that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Health Catalyst news, Director Duncan Gallagher sold 4,500 shares of Health Catalyst stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the completion of the sale, the director now directly owns 74,438 shares in the company, valued at $519,577.24. This trade represents a 5.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the transaction, the insider now owns 98,702 shares in the company, valued at approximately $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,169 shares of company stock valued at $639,174. 2.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Health Catalyst

Hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC grew its position in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after acquiring an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc boosted its stake in shares of Health Catalyst by 16.4% in the third quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after purchasing an additional 360,201 shares during the period. Millennium Management LLC boosted its stake in shares of Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after purchasing an additional 1,184,131 shares during the period. Primecap Management Co. CA grew its holdings in shares of Health Catalyst by 1.1% in the third quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Daventry Group LP increased its stake in Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after buying an additional 84,178 shares during the period. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.